SCHEMBL874437

SCHEMBL874437

CS(=O)(=O)OCc1ccc(OCc2ccccc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 4/20 0.62
RAB9A P51151 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
NPC1 O15118 1/20 0.62
HPGD P15428 1/20 0.62
CA12 O43570 1/20 0.58
CA1 P00915 1/20 0.58
CA2 P00918 1/20 0.58
CA4 P22748 1/20 0.58
CA5A P35218 1/20 0.58
CA7 P43166 1/20 0.58
CA9 Q16790 1/20 0.58
CA5B Q9Y2D0 1/20 0.58
PTGS1 P23219 2/20 0.55
PTGS2 P35354 2/20 0.55
ALOX5 P09917 1/20 0.55
LMNA P02545 1/20 0.55
CYP1A2 P05177 1/20 0.55
SLC6A2 P23975 1/20 0.55
CYP2C19 P33261 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5691423 0.87 AR (0.56) ARRAB9ASMN1; SMN2NPC1HPGD
Benzene SCHEMBL27447210 0.87 CA2 (0.63) ARRAB9ASMN1; SMN2NPC1HPGD
SCHEMBL249386 0.87 CA2 (0.63) ARRAB9ASMN1; SMN2NPC1HPGD
SCHEMBL5373770 0.87 AR (0.55) ARRAB9ASMN1; SMN2NPC1HPGD
SCHEMBL2805877 0.85 FFAR1 (0.58) ARRAB9ASMN1; SMN2NPC1HPGD
SCHEMBL2617478 0.85 MAOB (0.57) ARRAB9ASMN1; SMN2NPC1HPGD
SCHEMBL16295051 0.85 CA12 (0.62) ARRAB9ASMN1; SMN2NPC1HPGD
SCHEMBL4051544 0.85 CA12 (0.62) ARCA12CA1CA2CA7
SCHEMBL4167398 0.85 MGLL (0.49) ARRAB9ASMN1; SMN2NPC1HPGD
SCHEMBL3187746 0.85 MGLL (0.59) ARRAB9ASMN1; SMN2NPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2014-05-29 US disclosed
EP-2619185-A1 MATRIX METALLOPROTEINASE INHIBITORS Ranbaxy Laboratories Limited (IN) 2013-07-31 EP disclosed
WO-2012038942-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2012-03-29 WO disclosed
WO-2010010435-A2 FUSED OXAZOLE AND THIAZOLE DERIVATIVES AS TRPMS MODULATORS GLENMARK PHARMACEUTICAL S.A. (CH) 2010-01-28 WO disclosed
US-5811439-A ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION; ANTILEPEMIC AGENTS SENGA PHARMACEUTICAL LABORATORY INC. (JP) 1998-09-22 US disclosed
EP-0780389-A1 Thiazolidinedione derivatives, process for their preparation and pharmaceutical compositions containing them TOBISHI PHARMACEUTICAL CO., LTD. (JP) 1997-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS MMP9, MMP12, MMP10 AR 588/4885RAB9A 1310/4885SMN1; SMN2 3367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.